Screener
Ligand Pharmaceuticals LGND Revenue from intangible royalty assets — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues and income: | ||||
| Revenue from intangible royalty assets | $37,362 | $30,084 | $70,293 | $51,671 |
| Income from financial royalty assets | 10,670 | 6,313 | 20,697 | 12,215 |
| Royalties | 48,032 | 36,397 | 90,990 | 63,886 |
| Captisol | 7,978 | 8,287 | 16,632 | 21,747 |
| Contract revenue and income | 7,683 | 2,943 | 7,793 | 7,327 |
| Total revenues and income | 63,693 | 47,627 | 115,415 | 92,960 |
| Operating costs and expenses: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported revenue from intangible royalty assets — total revenues and income of $37.36M in Q2 2026.
- How has Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income increased by 24.2% year-over-year, from $30.08M to $37.36M.
- What is the long-term trend for Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income has grown at a 22.3% compound annual growth rate (CAGR), from $72.53M to $132.53M.
- What does revenue from intangible royalty assets — total revenues and income mean?
- This metric represents the total income generated from royalty streams associated with the company's portfolio of intangible pharmaceutical assets. It captures the recurring cash flows derived from licensing agreements and commercialized products developed through the company's technology platforms. This figure serves as a primary indicator of the long-term commercial success and market adoption of the drugs supported by the company's intellectual property.
Ask your AI about Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude